摘要
家族性地中海热(FMF)是最常见的遗传性自身炎症性综合症。FMF是由编码哌啉蛋白的MEFV基因突变引起的。FMF的临床特征是时有时无的,阵发性发作的发热和浆膜炎,持续时间为1-3天。患者可能发展成肾淀粉样变性。秋水仙素阻止疾病侵袭和肾淀粉样变性。有5%到10%的FMF患者耐药或不能耐受秋水仙碱。秋水仙素耐药的病人可以接受生物治疗。抗白介素-1药物是生物治疗的最重要药物。这篇综述,将对秋水仙碱耐药和治疗选择进行阐述。
关键词: 秋水仙碱耐药,家族性地中海热,治疗
Current Medicinal Chemistry
Title:Biological Agents in Familial Mediterranean Fever Focusing on Colchicine Resistance and Amyloidosis
Volume: 22 Issue: 16
Author(s): Betul Sozeri and Ozgur Kasapcopur
Affiliation:
关键词: 秋水仙碱耐药,家族性地中海热,治疗
摘要: Familial Mediterranean fever (FMF) is the most common hereditary autoinflammatory syndrome. FMF is caused by mutations in the MEFV gene which encodes the pyrin protein. FMF is characterized by sporadic, paroxysmal attacks of fever and serosal inflammation, lasting 1-3 days. Patients may develop renal amyloidosis. Colchicine prevents attacks and renal amyloidosis.5% to 10% of the patients with FMF are resistant or intolerant to colchicine. Colchicine resistant patients may receive biological therapies. Anti-interleukin-1 drugs are the most important agents of biological treatments. In this review, colchicine resistance and treatment options will be evaluated.
Export Options
About this article
Cite this article as:
Betul Sozeri and Ozgur Kasapcopur , Biological Agents in Familial Mediterranean Fever Focusing on Colchicine Resistance and Amyloidosis, Current Medicinal Chemistry 2015; 22 (16) . https://dx.doi.org/10.2174/0929867322666150311152300
DOI https://dx.doi.org/10.2174/0929867322666150311152300 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Blood Atherogenicity as a Target for Anti-atherosclerotic Therapy
Current Pharmaceutical Design Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis
Current Immunology Reviews (Discontinued) Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders
Current Pharmaceutical Design Novel Adjunctive Therapies for the Treatment of Tuberculosis
Current Molecular Medicine Hypersensitivity to Lamotrigine and Nonaromatic Anticonvulsant Drugs: A Review
Current Pharmaceutical Design Recognition of Classical and Heavy Chain Forms of HLA-B27 by Leukocyte Receptors
Current Molecular Medicine Ebola Virus Altered Innate and Adaptive Immune Response Signalling Pathways: Implications for Novel Therapeutic Approaches
Infectious Disorders - Drug Targets Henoch-Schönlein Purpura in Children: An Updated Review
Current Pediatric Reviews PD1/PD-L1 Axis in Uro-oncology
Current Drug Targets Rashes, Sniffles, and Stroke: A Role for Infection in Ischemic Stroke of Childhood
Infectious Disorders - Drug Targets Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design Endothelial Progenitor Cells as Mediators of the Crosstalk between Vascular Repair and Immunity: Lessons from Systemic Autoimmune Diseases
Current Medicinal Chemistry Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) Anti-inflammatory and Antioxidant Agents from Salvia Genus (Lamiaceae): An Assessment of the Current State of Knowledge
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry In Vitro and Ex Vivo Model Systems to Measure ABC Transporter Activity at the Blood-Brain Barrier
Current Pharmaceutical Design The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review
Current Cardiology Reviews Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Complement System in SLE as a Target for Antibodies
Current Rheumatology Reviews Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
Current Cardiology Reviews The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy
Current Drug Targets